

Dr. Antoni Ribas

Selected Publications:

1. Mark E. Davis, Jonathan E. Zuckerman, Chung Hang J. Choi... **Antoni Ribas**. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. **Nature** 2010 Apr 15; 464 (7291): 1067-70.
2. Fei Su, Amaya Viros, Carla Milagre... **Antoni Ribas***, Richard Marais*. RAS mutations in cutaneous squamous cell carcinomas with BRAF inhibitors. ***equal contribution** as corresponding and senior authors. **New England Journal of Medicine** 2012 January 19; 366: 207-15.
3. Jeffrey A. Sosman, Kevin B. Kim, Lynn Schuchter... **Antoni Ribas**. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. **New England Journal of Medicine** 2012 Feb 23; 366 (8): 707-14.
4. Omid Hamid, Caroline Robert, Adil Daud... **Antoni Ribas**. Safety and Tumor Responses with Lembroizumab (Anti PD-1) in Melanoma. **New England Journal of Medicine** 2013 Jul 11; 369 (2): 134-44.
5. Caroline Robert*, **Antoni Ribas***, Jedd D. Wolchok... Adil Daud. ***equal contribution**. Anti-PD-1 Treatment with MK-3475 in Ipilimumab-Refractory Advanced Melanoma. **The Lancet** 2014 Sep 20; 384 (9948): 1109-17
6. James Larkin, Paolo A. Ascierto, Brigitte Dréno... **Antoni Ribas**. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. **New England Journal of Medicine** 2014 Nov 13; 371 (20): 1867-76.
7. Paul C. Tumeh, Christina L. Harview, Jennifer H. Yearley... **Antoni Ribas**. PD-1 blockade induces responses by inhibiting adaptive immune resistance. **Nature** 2014 Nov 26; 515 (7528): 568-71
8. Caroline Robert, Jacob Schachter, Georgina V. Long... **Antoni Ribas**. Pembrolizumab versus ipilimumab in advanced melanoma. **New England Journal of Medicine** 2015 Jun 25; 372 (26): 2521-32.
9. **Antoni Ribas**, Omid Hamid, Adil Daud... Caroline Robert. Association of Pembrolizumab Administration with Tumor Response and Survival Among Patients with Advanced Melanoma. **Journal of the American Medical Association (JAMA)** 2016 Apr 19; 315 (15): 1600-9.
10. Jesse M. Zaretsky, Angel Garcia Diaz, Daniel Sanghoon Shin... **Antoni Ribas**. Mutations associated with acquired resistance to PD-1 blockade in melanoma. **New England Journal of Medicine** 2016 Sep; 375 (9): 819-29.
11. Daniel Sanghoon Shin, Jesse M. Zaretsky, Helena Escuin-Ordinas... **Antoni Ribas**. Primary resistance to PD-1 blockade mediated by *JAK1/2* mutations. **Cancer Discovery** 2017 Feb; 7 (2): 188-201.
12. **Antoni Ribas**, Reinhard Dummer, Igor Puzanov... Georgina V. Long. Oncolytic Virotherapy to Reverse Absence of Intratumoral T-Cell Infiltration and Improve Anti-PD-1 Immunotherapy. **Cell** 2017 Sep 7; 170 (6): 1109-1119.e10.

13. Zeynep Eroglu, Jesse M. Zaretsky, Siwen Hu-Lieskovan... **Antoni Ribas**. High response rate to PD-1 blockade in desmoplastic melanomas. **Nature** 2018 Jan 18; 553 (7688): 347-350.
14. **Antoni Ribas**, Donald Lawrence, Victoria Atkinson... Omid Hamid. Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in *BRAF*-mutant melanoma. **Nature Medicine** 2019 Jun; 25 (6): 936-940.
15. Gabriel Abril-Rodríguez, Davis Y. Torrejon, Wei Liu... **Antoni Ribas**. PAK4 inhibition improves PD-1 blockade immunotherapy. **Nature Cancer** 2020 Jan, 1 (2): 46–58.
16. Davis Y. Torrejon, Gabriel Abril-Rodríguez, Ameya Champhekar... **Antoni Ribas**. Overcoming genetically-based resistance mechanisms to PD-1 blockade. **Cancer Discovery** 2020 Aug; 10 (8): 1140-1157.
17. Catherine S. Grasso, Jennifer Tsoi, Mykola Onyshchenko... **Antoni Ribas**. Conserved Interferon- γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma. **Cancer Cell** 2020 Sep 8: S1535-6108 (20) 30416-5.
18. Alain P. Algazi, Megan Othus, Adil I. Daud... **Antoni Ribas**. Continuous compared to intermittent dabrafenib and trametinib in BRAF mutated melanoma. **Nature Medicine** 2020 Oct; 26 (10): 1564-1568.
19. Anusha Kalbasi, Kevin Hakimi, Katie Campbell... **Antoni Ribas**. Uncoupling interferon signaling and antigen presentation to overcome immunotherapy resistance due to JAK1 loss in melanoma. **Science Translational Medicine** 2020 Oct 14; 12 (565): eabb0152
20. Mario E. Lacouture, Zev A. Wainberg, Anisha B. Patel... **Antoni Ribas**. Reducing the skin toxicities from EGFR inhibitors with topical BRAF inhibitor therapy. **Cancer Discovery** 2021 Sep; 11 (9): 2158-2167.
21. **Antoni Ribas**, Rene Gonzales, John M. Kirkwood... Mohammed M. Milhem. Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma. **Cancer Discovery** 2021 Dec 1; 11 (12): 2998-3007.
22. Kenneth F. Grossmann, Megan Othus, Sapna P. Patel... **Antoni Ribas**. Adjuvant pembrolizumab versus interferon alfa-2b or ipilimumab in resected high-risk melanoma. **Cancer Discovery** 2022 Mar 1; 12 (3): 644-653.
23. Anusha Kalbasi*, Mikko Siurala, Leon Su... **Antoni Ribas***, Carl H. June*, K. Christopher Garcia*, ***equal contribution** as corresponding and senior authors. Potentiating adoptive cell therapy using synthetic IL-9 receptors. **Nature** 2022 Jul; 607 (7918): 360-365.